Ying Luo - 08 Jun 2026 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: GYRE
Reported as of: 08 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 16:13:08 UTC
Prior SEC filing: 07 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas Eastling, as attorney-in-fact for Ying Luo

Key filing fact

Ying Luo filed Form 4 for GYRE THERAPEUTICS, INC. (GYRE) on 10 Jun 2026.

Key facts

This page summarizes Ying Luo's Form 4 filing for GYRE THERAPEUTICS, INC. (GYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2026, 16:13.

Change

Previous filing in this sequence was filed on 07 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001959160 Primary reporting owner

Luo Ying

Relationship: Chief Executive Officer, Director
Address: C/O GYRE THERAPEUTICS, INC., 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO
Signature: /s/ Thomas Eastling, as attorney-in-fact for Ying Luo
Signature date: 10 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GYRE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +120,000
Change %
Price: $0.000000^*
Shares after: 120,000
Date: 08 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price: $6.05
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.